Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mycoses | 8 | 2018 | 387 | 2.320 |
Why?
|
Antifungal Agents | 10 | 2022 | 749 | 1.760 |
Why?
|
Aspergillosis | 7 | 2019 | 243 | 1.700 |
Why?
|
Mannans | 4 | 2018 | 58 | 1.580 |
Why?
|
beta-Glucans | 7 | 2020 | 121 | 1.390 |
Why?
|
Volatile Organic Compounds | 2 | 2021 | 84 | 0.840 |
Why?
|
Communicable Diseases | 3 | 2021 | 878 | 0.780 |
Why?
|
Ascomycota | 2 | 2012 | 81 | 0.730 |
Why?
|
Breath Tests | 2 | 2021 | 297 | 0.720 |
Why?
|
Pulmonary Aspergillosis | 1 | 2018 | 47 | 0.610 |
Why?
|
False Positive Reactions | 2 | 2018 | 956 | 0.600 |
Why?
|
Immunocompromised Host | 5 | 2015 | 857 | 0.570 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2022 | 1375 | 0.540 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2018 | 748 | 0.540 |
Why?
|
Disk Diffusion Antimicrobial Tests | 1 | 2015 | 8 | 0.530 |
Why?
|
Candidemia | 1 | 2015 | 38 | 0.510 |
Why?
|
Fluconazole | 1 | 2015 | 155 | 0.500 |
Why?
|
Cephalosporins | 1 | 2016 | 204 | 0.490 |
Why?
|
Lung Transplantation | 3 | 2017 | 1305 | 0.490 |
Why?
|
Neuralgia, Postherpetic | 1 | 2013 | 41 | 0.440 |
Why?
|
Antigens, Fungal | 2 | 2012 | 69 | 0.440 |
Why?
|
Aspergillus fumigatus | 1 | 2014 | 156 | 0.430 |
Why?
|
Clinical Laboratory Techniques | 1 | 2018 | 749 | 0.430 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2012 | 245 | 0.420 |
Why?
|
Opportunistic Infections | 1 | 2015 | 377 | 0.420 |
Why?
|
Parainfluenza Virus 3, Human | 1 | 2012 | 25 | 0.410 |
Why?
|
Heart Transplantation | 3 | 2017 | 3224 | 0.410 |
Why?
|
Candidiasis, Invasive | 1 | 2012 | 23 | 0.400 |
Why?
|
Paramyxoviridae Infections | 1 | 2012 | 57 | 0.400 |
Why?
|
Anti-Infective Agents, Local | 1 | 2014 | 247 | 0.380 |
Why?
|
Mycophenolic Acid | 1 | 2013 | 343 | 0.380 |
Why?
|
Herpes Zoster | 1 | 2013 | 251 | 0.370 |
Why?
|
Galactose | 4 | 2018 | 297 | 0.370 |
Why?
|
Neutropenia | 1 | 2016 | 884 | 0.360 |
Why?
|
Central Nervous System Fungal Infections | 1 | 2010 | 24 | 0.360 |
Why?
|
Hematologic Neoplasms | 4 | 2020 | 1895 | 0.350 |
Why?
|
Cytomegalovirus Infections | 5 | 2020 | 831 | 0.350 |
Why?
|
Cellulitis | 1 | 2012 | 207 | 0.350 |
Why?
|
Catheterization, Central Venous | 1 | 2014 | 526 | 0.320 |
Why?
|
Myositis | 1 | 2012 | 269 | 0.320 |
Why?
|
Triazoles | 4 | 2019 | 904 | 0.310 |
Why?
|
Cord Blood Stem Cell Transplantation | 3 | 2018 | 305 | 0.300 |
Why?
|
Ethanol | 1 | 2014 | 1323 | 0.290 |
Why?
|
Transplantation, Homologous | 6 | 2018 | 4810 | 0.290 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2022 | 5649 | 0.290 |
Why?
|
Cytomegalovirus | 4 | 2020 | 755 | 0.280 |
Why?
|
Immunosuppressive Agents | 4 | 2013 | 4166 | 0.270 |
Why?
|
Recombinant Fusion Proteins | 2 | 2012 | 3735 | 0.260 |
Why?
|
Anti-Bacterial Agents | 3 | 2024 | 7408 | 0.250 |
Why?
|
Proteoglycans | 5 | 2012 | 801 | 0.240 |
Why?
|
Candidiasis | 2 | 2021 | 363 | 0.240 |
Why?
|
Organ Transplantation | 4 | 2024 | 1150 | 0.230 |
Why?
|
Extracorporeal Membrane Oxygenation | 3 | 2020 | 1459 | 0.230 |
Why?
|
Frontal Lobe | 1 | 2010 | 1420 | 0.220 |
Why?
|
Graft Rejection | 2 | 2013 | 4426 | 0.220 |
Why?
|
Physicians | 1 | 2021 | 4591 | 0.210 |
Why?
|
Aged | 33 | 2024 | 169152 | 0.210 |
Why?
|
Immunologic Factors | 2 | 2018 | 1588 | 0.200 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2024 | 238 | 0.200 |
Why?
|
Immunoassay | 2 | 2020 | 746 | 0.200 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 9185 | 0.200 |
Why?
|
Middle Aged | 36 | 2024 | 220352 | 0.200 |
Why?
|
Histoplasma | 2 | 2011 | 39 | 0.200 |
Why?
|
Cardiomyopathies | 1 | 2013 | 1952 | 0.190 |
Why?
|
Histoplasmosis | 2 | 2011 | 63 | 0.190 |
Why?
|
Young Adult | 13 | 2020 | 58741 | 0.180 |
Why?
|
Adult | 30 | 2024 | 219994 | 0.180 |
Why?
|
Glucans | 1 | 2020 | 68 | 0.170 |
Why?
|
Transplants | 1 | 2022 | 206 | 0.170 |
Why?
|
Respiratory Insufficiency | 2 | 2019 | 1231 | 0.170 |
Why?
|
Sepsis | 1 | 2014 | 2592 | 0.170 |
Why?
|
Male | 39 | 2024 | 359744 | 0.170 |
Why?
|
Humans | 57 | 2024 | 760621 | 0.170 |
Why?
|
Leukemia | 1 | 2008 | 1520 | 0.170 |
Why?
|
Pneumocystis carinii | 2 | 2012 | 72 | 0.160 |
Why?
|
Aged, 80 and over | 12 | 2020 | 58995 | 0.160 |
Why?
|
Polydeoxyribonucleotides | 1 | 2020 | 138 | 0.160 |
Why?
|
Adrenal Glands | 2 | 2011 | 554 | 0.160 |
Why?
|
Fever | 3 | 2018 | 1617 | 0.160 |
Why?
|
Lymphoma | 1 | 2008 | 1898 | 0.160 |
Why?
|
Orchitis | 1 | 2018 | 35 | 0.160 |
Why?
|
Encephalitis, Tick-Borne | 1 | 2018 | 37 | 0.150 |
Why?
|
Female | 34 | 2024 | 391270 | 0.150 |
Why?
|
Encephalitis Viruses, Tick-Borne | 1 | 2018 | 43 | 0.150 |
Why?
|
Respiratory Tract Infections | 2 | 2020 | 1007 | 0.150 |
Why?
|
Uveitis | 2 | 2011 | 393 | 0.150 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2020 | 611 | 0.150 |
Why?
|
Encephalitozoon cuniculi | 1 | 2017 | 5 | 0.150 |
Why?
|
Bacteremia | 1 | 2024 | 980 | 0.140 |
Why?
|
Microsporidiosis | 1 | 2017 | 23 | 0.140 |
Why?
|
Cohort Studies | 11 | 2019 | 41335 | 0.140 |
Why?
|
Photopheresis | 1 | 2017 | 35 | 0.140 |
Why?
|
Viruses | 1 | 2020 | 376 | 0.140 |
Why?
|
Heart Defects, Congenital | 1 | 2013 | 4673 | 0.140 |
Why?
|
Anticoagulants | 4 | 2005 | 4897 | 0.140 |
Why?
|
Propensity Score | 1 | 2024 | 1928 | 0.140 |
Why?
|
Primary Graft Dysfunction | 1 | 2017 | 111 | 0.130 |
Why?
|
Treatment Outcome | 13 | 2024 | 65017 | 0.130 |
Why?
|
Retrospective Studies | 14 | 2024 | 80372 | 0.130 |
Why?
|
Incidence | 6 | 2022 | 21392 | 0.130 |
Why?
|
Hemorrhage | 2 | 2004 | 3600 | 0.130 |
Why?
|
Cyclohexenes | 1 | 2014 | 15 | 0.120 |
Why?
|
Monoterpenes | 1 | 2014 | 22 | 0.120 |
Why?
|
Lung Diseases, Fungal | 1 | 2015 | 126 | 0.120 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13630 | 0.120 |
Why?
|
Risk Factors | 10 | 2022 | 74359 | 0.120 |
Why?
|
Terpenes | 1 | 2014 | 96 | 0.120 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2014 | 352 | 0.110 |
Why?
|
Decision Trees | 1 | 2015 | 506 | 0.110 |
Why?
|
Sesquiterpenes | 1 | 2014 | 176 | 0.110 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2013 | 37 | 0.110 |
Why?
|
Species Specificity | 1 | 2018 | 2418 | 0.110 |
Why?
|
Leukemia, Prolymphocytic, T-Cell | 1 | 2013 | 23 | 0.110 |
Why?
|
Encephalomyelitis | 1 | 2013 | 36 | 0.110 |
Why?
|
Encephalitis | 1 | 2017 | 437 | 0.110 |
Why?
|
Ganciclovir | 1 | 2013 | 252 | 0.110 |
Why?
|
Immunomodulation | 1 | 2017 | 547 | 0.110 |
Why?
|
Adenoviridae Infections | 1 | 2013 | 93 | 0.100 |
Why?
|
Echinocandins | 1 | 2012 | 51 | 0.100 |
Why?
|
DNA, Ribosomal Spacer | 1 | 2012 | 27 | 0.100 |
Why?
|
Reagent Strips | 1 | 2012 | 39 | 0.100 |
Why?
|
Lipopeptides | 1 | 2012 | 72 | 0.100 |
Why?
|
Tissue Transplantation | 1 | 2012 | 128 | 0.100 |
Why?
|
Serum | 2 | 2011 | 211 | 0.100 |
Why?
|
Amphotericin B | 1 | 2012 | 142 | 0.100 |
Why?
|
Epidemiologic Studies | 1 | 2015 | 670 | 0.100 |
Why?
|
Limbic Encephalitis | 1 | 2012 | 36 | 0.100 |
Why?
|
Immunotherapy | 1 | 2008 | 4642 | 0.100 |
Why?
|
Marital Status | 1 | 2013 | 433 | 0.100 |
Why?
|
Cytosine | 1 | 2013 | 212 | 0.100 |
Why?
|
Aspergillus | 1 | 2012 | 92 | 0.100 |
Why?
|
Roseolovirus Infections | 1 | 2012 | 50 | 0.100 |
Why?
|
Cystectomy | 1 | 2017 | 697 | 0.100 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 643 | 0.100 |
Why?
|
Herpesvirus 6, Human | 1 | 2012 | 97 | 0.100 |
Why?
|
Drug Administration Schedule | 3 | 2015 | 4899 | 0.100 |
Why?
|
Candida | 1 | 2012 | 173 | 0.090 |
Why?
|
Equipment Contamination | 1 | 2012 | 179 | 0.090 |
Why?
|
DNA, Ribosomal | 1 | 2012 | 285 | 0.090 |
Why?
|
DNA, Fungal | 1 | 2012 | 275 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2015 | 1180 | 0.090 |
Why?
|
Time Factors | 7 | 2019 | 40165 | 0.090 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 1677 | 0.090 |
Why?
|
Diagnostic Tests, Routine | 1 | 2015 | 786 | 0.090 |
Why?
|
Anti-Infective Agents | 2 | 2014 | 981 | 0.080 |
Why?
|
Graft vs Host Disease | 3 | 2012 | 3025 | 0.080 |
Why?
|
Histocytochemistry | 1 | 2010 | 700 | 0.080 |
Why?
|
Dacarbazine | 1 | 2012 | 560 | 0.080 |
Why?
|
Kidney Transplantation | 2 | 2017 | 4215 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 693 | 0.080 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2012 | 618 | 0.080 |
Why?
|
Respiration, Artificial | 1 | 2019 | 2622 | 0.070 |
Why?
|
Seminal Vesicles | 2 | 2005 | 107 | 0.070 |
Why?
|
Drug Costs | 1 | 2015 | 1185 | 0.070 |
Why?
|
Tissue Donors | 1 | 2017 | 2313 | 0.070 |
Why?
|
Aminoglycosides | 1 | 2008 | 163 | 0.070 |
Why?
|
Fatal Outcome | 3 | 2018 | 1832 | 0.070 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4353 | 0.070 |
Why?
|
Leg | 1 | 2012 | 1090 | 0.070 |
Why?
|
Lung Diseases | 1 | 2017 | 1915 | 0.070 |
Why?
|
Republic of Korea | 2 | 2019 | 566 | 0.070 |
Why?
|
Face | 1 | 2012 | 1017 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2010 | 448 | 0.070 |
Why?
|
Antibodies, Neoplasm | 1 | 2008 | 280 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2019 | 12159 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2017 | 2283 | 0.070 |
Why?
|
Immunity, Humoral | 1 | 2010 | 604 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2020 | 12531 | 0.070 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4550 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 8552 | 0.060 |
Why?
|
Treatment Failure | 1 | 2012 | 2648 | 0.060 |
Why?
|
Survival Rate | 3 | 2019 | 12808 | 0.060 |
Why?
|
Warfarin | 2 | 2004 | 1518 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2016 | 2754 | 0.060 |
Why?
|
Microscopy | 1 | 2010 | 885 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 10344 | 0.060 |
Why?
|
Liver Transplantation | 1 | 2017 | 2325 | 0.060 |
Why?
|
Cluster Analysis | 1 | 2012 | 2698 | 0.060 |
Why?
|
Sirolimus | 1 | 2012 | 1547 | 0.060 |
Why?
|
Prognosis | 4 | 2020 | 29658 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2015 | 5201 | 0.060 |
Why?
|
Radiotherapy, Conformal | 2 | 2005 | 549 | 0.060 |
Why?
|
Prostate-Specific Antigen | 2 | 2005 | 2529 | 0.060 |
Why?
|
Boston | 2 | 2016 | 9280 | 0.060 |
Why?
|
Phylogeny | 1 | 2012 | 2775 | 0.060 |
Why?
|
Adolescent | 7 | 2020 | 87810 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2011 | 1266 | 0.060 |
Why?
|
Kinetics | 1 | 2012 | 6377 | 0.060 |
Why?
|
Antiviral Agents | 2 | 2013 | 3061 | 0.060 |
Why?
|
Medication Systems, Hospital | 1 | 2004 | 154 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14660 | 0.060 |
Why?
|
Thromboembolism | 3 | 2005 | 1017 | 0.060 |
Why?
|
Surgical Wound Infection | 1 | 2012 | 1527 | 0.050 |
Why?
|
Recurrence | 1 | 2015 | 8482 | 0.050 |
Why?
|
Bandages | 1 | 2005 | 270 | 0.050 |
Why?
|
Influenza Vaccines | 1 | 2010 | 766 | 0.050 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2004 | 198 | 0.050 |
Why?
|
Adrenal Cortex Hormones | 1 | 2012 | 1869 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5508 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2017 | 15697 | 0.050 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2011 | 1067 | 0.050 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2004 | 345 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15289 | 0.050 |
Why?
|
Health Care Costs | 1 | 2015 | 3258 | 0.050 |
Why?
|
Anti-Inflammatory Agents | 1 | 2012 | 1796 | 0.050 |
Why?
|
Reminder Systems | 1 | 2005 | 387 | 0.050 |
Why?
|
Massachusetts | 1 | 2014 | 8803 | 0.050 |
Why?
|
Cause of Death | 1 | 2012 | 3725 | 0.050 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 4713 | 0.050 |
Why?
|
GATA2 Transcription Factor | 1 | 2021 | 158 | 0.040 |
Why?
|
Risk | 1 | 2012 | 9631 | 0.040 |
Why?
|
Heparin | 2 | 2004 | 1652 | 0.040 |
Why?
|
Sex Factors | 1 | 2013 | 10547 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 424 | 0.040 |
Why?
|
Radiography | 1 | 2010 | 6965 | 0.040 |
Why?
|
Stem Cell Transplantation | 1 | 2008 | 1599 | 0.040 |
Why?
|
Influenza, Human | 1 | 2010 | 1528 | 0.040 |
Why?
|
Antibodies, Viral | 1 | 2010 | 3143 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2012 | 17624 | 0.040 |
Why?
|
Myasthenia Gravis | 2 | 2011 | 213 | 0.040 |
Why?
|
North America | 1 | 2022 | 1284 | 0.040 |
Why?
|
Neoplasms | 2 | 2021 | 22072 | 0.040 |
Why?
|
APACHE | 1 | 2019 | 267 | 0.040 |
Why?
|
Cell Count | 1 | 2022 | 1835 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2014 | 39261 | 0.040 |
Why?
|
Medication Errors | 1 | 2004 | 784 | 0.040 |
Why?
|
Pyrimidines | 1 | 2010 | 3016 | 0.040 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2020 | 220 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 11712 | 0.040 |
Why?
|
Blood Glucose | 1 | 2012 | 6381 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2019 | 2852 | 0.040 |
Why?
|
Length of Stay | 2 | 2024 | 6479 | 0.040 |
Why?
|
Adenocarcinoma | 2 | 2005 | 6315 | 0.040 |
Why?
|
Glioblastoma | 1 | 2012 | 3484 | 0.030 |
Why?
|
Age Factors | 1 | 2013 | 18416 | 0.030 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 1628 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 4357 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4035 | 0.030 |
Why?
|
Risk Assessment | 3 | 2014 | 24123 | 0.030 |
Why?
|
Prospective Studies | 2 | 2014 | 54303 | 0.030 |
Why?
|
Area Under Curve | 1 | 2020 | 1636 | 0.030 |
Why?
|
Decision Support Systems, Clinical | 1 | 2005 | 1164 | 0.030 |
Why?
|
Hospital Mortality | 2 | 2020 | 5425 | 0.030 |
Why?
|
Venous Thrombosis | 1 | 2005 | 1299 | 0.030 |
Why?
|
Acute Disease | 2 | 2019 | 7269 | 0.030 |
Why?
|
Nitriles | 1 | 2019 | 956 | 0.030 |
Why?
|
Fatigue | 2 | 2011 | 1544 | 0.030 |
Why?
|
Software | 2 | 2005 | 4419 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 2011 | 5130 | 0.030 |
Why?
|
Bacteria, Aerobic | 1 | 2012 | 25 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1454 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3113 | 0.030 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 685 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2019 | 3465 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 1998 | 1075 | 0.030 |
Why?
|
Bacteria, Anaerobic | 1 | 2012 | 70 | 0.030 |
Why?
|
ROC Curve | 1 | 2020 | 3568 | 0.020 |
Why?
|
Drug Dosage Calculations | 1 | 2012 | 118 | 0.020 |
Why?
|
Prostatic Neoplasms | 2 | 2005 | 11345 | 0.020 |
Why?
|
Fetal Blood | 1 | 2018 | 1343 | 0.020 |
Why?
|
Phlebotomy | 1 | 2012 | 137 | 0.020 |
Why?
|
Pulmonary Embolism | 1 | 2005 | 2543 | 0.020 |
Why?
|
Severity of Illness Index | 3 | 2019 | 15840 | 0.020 |
Why?
|
Hodgkin Disease | 1 | 1998 | 1378 | 0.020 |
Why?
|
Virus Activation | 1 | 2012 | 319 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2010 | 36290 | 0.020 |
Why?
|
Weight Loss | 2 | 2011 | 2686 | 0.020 |
Why?
|
United States | 3 | 2017 | 72461 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5877 | 0.020 |
Why?
|
Catheter-Related Infections | 1 | 2012 | 273 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2020 | 5870 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1547 | 0.020 |
Why?
|
SEER Program | 1 | 2013 | 1530 | 0.020 |
Why?
|
Drug Synergism | 1 | 2012 | 1754 | 0.020 |
Why?
|
Radiotherapy Dosage | 2 | 2005 | 2897 | 0.020 |
Why?
|
Pyridines | 1 | 2019 | 2879 | 0.020 |
Why?
|
Cytokines | 1 | 2020 | 7343 | 0.020 |
Why?
|
Disease-Free Survival | 2 | 2005 | 6828 | 0.010 |
Why?
|
Social Support | 1 | 2013 | 2145 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2012 | 6238 | 0.010 |
Why?
|
Hospital Information Systems | 1 | 2005 | 394 | 0.010 |
Why?
|
Graft Survival | 1 | 2012 | 3794 | 0.010 |
Why?
|
Chronic Disease | 1 | 2017 | 9287 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2012 | 6498 | 0.010 |
Why?
|
Odds Ratio | 1 | 2013 | 9716 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 2005 | 1975 | 0.010 |
Why?
|
Pneumonia | 1 | 2012 | 2131 | 0.010 |
Why?
|
Risk Management | 1 | 2004 | 558 | 0.010 |
Why?
|
Survival Analysis | 1 | 2012 | 10182 | 0.010 |
Why?
|
Sex Distribution | 1 | 2004 | 2295 | 0.010 |
Why?
|
Probability | 1 | 2004 | 2475 | 0.010 |
Why?
|
Medical Records Systems, Computerized | 1 | 2005 | 1191 | 0.010 |
Why?
|
Intracranial Hemorrhages | 1 | 2004 | 844 | 0.010 |
Why?
|
Age Distribution | 1 | 2004 | 2893 | 0.010 |
Why?
|
Costa Rica | 1 | 1998 | 177 | 0.010 |
Why?
|
Reed-Sternberg Cells | 1 | 1998 | 72 | 0.010 |
Why?
|
Viral Matrix Proteins | 1 | 1998 | 197 | 0.010 |
Why?
|
Prostate | 1 | 2005 | 1793 | 0.010 |
Why?
|
Mutation | 1 | 2021 | 29932 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2004 | 3618 | 0.010 |
Why?
|
Forecasting | 1 | 2005 | 2932 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2005 | 2176 | 0.010 |
Why?
|
Biopsy | 1 | 2005 | 6771 | 0.010 |
Why?
|
Immunophenotyping | 1 | 1998 | 1871 | 0.010 |
Why?
|
Patient Care Team | 1 | 2004 | 2511 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10827 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1998 | 6068 | 0.000 |
Why?
|
Research Design | 1 | 2004 | 6180 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 20509 | 0.000 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2005 | 9276 | 0.000 |
Why?
|
Animals | 1 | 2018 | 167963 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1998 | 11071 | 0.000 |
Why?
|
Hospitalization | 1 | 2004 | 10790 | 0.000 |
Why?
|
Socioeconomic Factors | 1 | 1998 | 7806 | 0.000 |
Why?
|
Cross-Sectional Studies | 1 | 2004 | 25942 | 0.000 |
Why?
|